Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function

Genes and Cancer

Volumn 3, Issue 11-12, 2012, Pages 619-633

  MacDonald, James I ^a   Dick, Frederick A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Acetylation; Cell cycle; Methylation; Phosphorylation; Proteomics

Indexed keywords

ABELSON KINASE; APOPTOSIS SIGNAL REGULATING KINASE 1; AURORA KINASE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 9; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE; RAF PROTEIN; RETINOBLASTOMA PROTEIN; SERINE; THREONINE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ACETYLATION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SUMOYLATION; UBIQUITINATION;

EID: 84880486381     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473305     Document Type: Review

References (188)

1. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996;274(5293):1664-72.
2. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672-7.
3. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220-7.
4. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12(15):2245-62.
5. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910-7.
6. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A. 1997;94(14):7245-50.
7. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med. 2006;6:739-48.
8. Ho A, Dowdy SF. Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 2002;12(1): 47-52.
9. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2(2):103-12.
10. Chauveinc L, Mosseri V, Quintana E, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet. 2001;22(2):77-88.
11. Sachdeva UM, O'Brien JM. Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma. J Clin Invest. 2012;122(2):425-34.
12. Wickenheiser-Brokamp KA. Retinoblastoma pathway in lung cancer. Curr Mol Med. 2006;6:783-93.
13. Kaye FJ, Harbour JW. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst. 2004;96(5):342-3.
14. Gordon G, Du W. Conserved RB functions in development and tumor suppression. Protein Cell. 2011;2(11):864-8.
15. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671-82.
16. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger P. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle. 2010;9(4):689-99.
17. Xin F, Radivojac P. Posttranslational modifications induce significant yet not extreme changes to protein structure. Bioinformatics. 2012; 28(22):2905-2913.
18. Munro S, Carr SM, La Thangue NB. Diversity within the pRb pathway: is there a code of conduct[quest]. Oncogene. 2012;31(40):4343-52.
19. Burke JR, Deshong AJ, Pelton JG, Rubin SM. Phosphorylation-induced conformational changes in the retinoblastoma protein Inhibit E2F transactivation domain binding. J Biol Chem. 2010;285(21):16286-93.
20. Burke JR, Hura GL, Rubin SM. Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev. 2012;26(11):1156-66.
21. Coller HA. What's taking so long? S-phase entry from quiescence versus proliferation. Nat Rev Mol Cell Biol. 2007;8(8):667-70.
22. Ianari A, Natale T, Calo E, et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell. 2009;15(3):184-94.
23. Cecchini MJ, Dick FA. The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein. Biochem J. 2011;434(2):297-308.
24. Carnevale J, Palander O, Seifried LA, Dick FA. DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol. 2012;32(5):900-12.
25. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J. 1999;18(6):1559-70.
26. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene. 2003;22(38):5986-94.
27. Hou ST, Xie X, Baggley A, Park DS, Chen G, Walker T. Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during Fas (APO1/CD95)-mediated neuronal apoptosis. J Biol Chem. 2002;277(50):48764-70.
28. Yeste-Velasco M, Folch J, Pallàs M, Camins A. The p38MAPK signaling pathway regulates neuronal apoptosis through the phosphorylation of the retinoblastoma protein. Neurochem Int. 2009;54(2):99-105.
29. Dick F. Structure-function analysis of the retinoblastoma tumor suppressor protein-is the whole a sum of its parts? Cell Division. 2007;2(1):26.
30. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, Thangue NBL. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol. 2001;3(7):667-74.
31. Nguyen DX, Baglia LA, Huang S-M, Baker CM, McCance DJ. Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J. 2004;23(7):1609-18.
32. Pickard A, Wong P-P, McCance DJ. Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation. J Cell Sci. 2010;123(21):3718-26.
33. Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB. Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J. 2011;30(2):317-27.
34. Saddic LA, West LE, Aslanian A, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010;285(48):37733-40.
35. Uchida C, Miwa S, Kitagawa K, et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 2005;24(1):160-9.
36. Miwa S, Uchida C, Kitagawa K, et al. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner. Biochem Biophys Res Comm. 2006;340(1):54-61.
37. Ledl A, Schmidt D, Muller S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene. 2005;24(23):3810-8.
38. Bischof O, Schwamborn K, Martin N, et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell. 2006;22(6):783-94.
39. Li T, Santockyte R, Shen R-F, et al. Expression of SUMO-2/3 induced senescence through p53-and pRB-mediated pathways. J Biol Chem. 2006;281(47):36221-7.
40. Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell. 1989;58(6):1097-105.
41. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A. 1997;94(20):10699-704.
42. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclindependent kinase complexes in vivo. Mol Cell Biol. 2001;21(14):4773-84.
43. Ubersax JA, Ferrell Jr JE. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 2007;8(7):530-41.
44. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol. 1999;19(5):3246-56.
45. Lents NH, Gorges LL, Baldassare JJ. Reverse mutational analysis reveals threonine-373 as a potentially sufficient phosphorylation site for inactivation of the retinoblastoma tumor suppressor protein (pRB). Cell Cycle. 2006;5(15): 1699-707.
46. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272(19):12738-46.
47. Kitagawa M, Higashi H, HK J, et al. The consensus sequence for phosphorylation by CyclinD1-Cdk4 is different from that for phosphorylation by Cyclin A/E-Cdk2. EMBO J. 1996;15(24):7060-9.
48. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phopshorylated on multiple sites by human cdc2. EMBO J. 1991;10(13):4179-290.
49. Harbour JW, Luo RX, Santi AD, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98(6):859-69.
50. Huttlin EL, Jedrychowski MP, Elias JE, et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell. 2010;143(7):1174-89.
51. Dephoure N, Zhou C, Villén J, et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008;105(31):10762-7.
52. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8(2):287-301.
53. Olsen JV, Vermeulen M, Santamaria A, et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010;3(104):ra3.
54. Choudhary C, Olsen JV, Brandts C, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326-39.
55. Old WM, Shabb JB, Houel S, et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell. 2009;34(1):115-31.
56. Mayya V, Lundgren DH, Hwang S-I, et al. Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009;2(84):ra46-.
57. Hornbeck PV, Kornhauser JM, Tkachev S, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined posttranslational modifications in man and mouse. Nucleic Acids Res. 2012;40(D1):D261-70.
58. Chow KN, Dean DC. Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol Cell Biol. 1996;16(9):4862-8.
59. Chow KN, Starostik P, Dean DC. The Rb family contains a conserved cyclin-dependent-kinaseregulated transcriptional repressor motif. Mol Cell Biol. 1996;16(12):7173-81.
60. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. 1997;17(10):5771-83.
61. Rubin SM, Gall A-L, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylationinduced E2F release. Cell. 2005;123(6):1093-106.
62. Takaki T, Fukasawa K, Suzuki-Takahashi I, Hirai H. Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro. Biochem Biophys Res Comm. 2004;316(1):252-5.
63. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391(6667):597-601.
64. Romano G, Giordano A. Role of the cyclindependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008;7(23):3664-8.
65. Yu DS, Zhao R, Hsu EL, et al. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep. 2010;11(11):876-82.
66. De Luca A, Esposito V, Baldi A, et al. CDC2-related kinase PITALRE phosphorylates pRb exclusively on serine and is widely expressed in human tissues. J Cell Physiol. 1997;172(2):265-73.
67. Graña X, De Luca A, Sang N, et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A. 1994;91(9):3834-8.
68. Simone C, Bagella L, Bellan C, Giordano A. Physical interaction between pRb and cdk9/ cyclinT2 complex. Oncogene. 2002;21(26):4158-65.
69. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 1998;12(5):755-62.
70. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 2003;424(6945):223-8.
71. Liu Z-J, Ueda T, Miyazaki T, et al. A critical role for cyclin C in promotion of the hematopoietic cell cycle by cooperation with c-Myc. Mol Cell Biol. 1998;18(6):3445-54.
72. Ren S, Rollins BJ. Cyclin C/Cdk3 promotes Rbdependent G0 exit. Cell. 2004;117(2):239-51.
73. Bonda DJ, Bajić VP, Spremo-Potparevic B, et al. Cell cycle aberrations and neurodegeneration. Neuropathol Appl Neurobiol. 2010;36(2):157-63.
74. Bonda DJ, Lee H-p, Kudo W, Zhu X, Smith MA, Lee H-g. Pathological implications of cell cycle re-entry in Alzheimer disease. Expert Rev Mol Med. 2010;12: e19.
75. Lee H-g, Casadesus G, Zhu X, et al. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009;54(2):84-8.
76. Zhang J, Cicero SA, Wang L, Romito-DiGiacomo RR, Yang Y, Herrup K. Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons. Proc Natl Acad Sci U S A. 2008;105(25):8772-7.
77. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K. Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci. 2010;30(15):5219-28.
78. Zhang J, Herrup K. Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in postmitotic neurons. Cell Cycle. 2011;10(8):1208-14.
79. Dhavan R, Tsai L-H. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2(10):749-59.
80. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F·DP, in B-amyloid-induced neuronal death. J Biol Chem. 1999;274(27):19011-6.
81. Ranganathan S, Scudiere S, Bowser R. Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer's disease and amyotrophic lateral sclerosis. J Alzheimers Dis. 2001;3(4):377-85.
82. Zhang J, Krishnamurthy PK, Johnson GVW. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem. 2002;81(2):307-13.
83. Hamdane M, Bretteville A, Sambo A-V, et al. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci. 2005;118(6):1291-8.
84. Fatasugi A, Utreras E, Rudrabhatla P, Jaffe H, Pant H, Kulkami AB. Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons. Cell Cycle. 2012;11(8):1603-10.
85. Faust D, Schmitt C, Oesch F, et al. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun Signal. 2012;10(1):6.
86. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38MAPK: stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15(8):369-79.
87. Thornton TM, Rincon M. Non-classical p38 MAP kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5(1):44-52.
88. Pillai MS, Sapna S, Shivakumar K. p38 MAPK regulates G1-S transition in hypoxic cardiac fibroblasts. Int J Biochem Cell Biol. 2011;43(6):919-27.
89. Delston RB, Matatall KA, Sun Y, Onken MD, Harbour JW. p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. Oncogene. 2011;30(5):588-99.
90. Cho HJ, Park S-M, Hwang EM, et al. Gadd45b mediates Fas-induced apoptosis by enhancing the interaction between p38 and retinoblastoma tumor suppressor. J Biol Chem. 2010;285(33):25500-5.
91. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100-12.
92. Qi M, Elion EA. MAP kinase pathways. J Cell Sci. 2005;118(16):3569-72.
93. Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001; 411(6833):102-7.
94. Cox DM, Du M, Marback M, et al. Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A. J Biol Chem. 2003;278(17):15297-303.
95. Cao X, Rui L, Pennington PR, et al. Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity. J Neurochem. 2009;111(1):101-10.
96. Sheridan DL, Kong Y, Parker SA, Dalby KN, Turk BE. Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. J Biol Chem. 2008;283(28):19511-20.
97. Stracker TH, Usui T, Petrini JHJ. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair. 2009;8(9): 1047-54.
98. Sørensen CS, Syljuåsen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40(2):477-86.
99. Inoue Y, Kitagawa M, Taya Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J. 2007;26(8):2083-93.
100. F BS, A CD. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest. 2012;122(4):1138-43.
101. Sage J, Straight AF. RB's original CIN? Genes Dev. 2010;24(13):1329-33.
102. Iovino F, Lentini L, Amato A, Di Leonardo A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer. 2006;5(1):38.
103. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 2010;24(13):1364-76.
104. Coschi CH, Martens AL, Ritchie K, et al. Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive. Genes Dev. 2010;24(13):1351-63.
105. van der Waal MS, Hengeveld RCC, van der, Horst A, Lens SMA. Cell division control by the chromosomal passenger complex. Exp Cell Res. 2012;318(12):1407-20.
106. Vader G, Lens SMA. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60-72.
107. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011;155(5):561-79.
108. Nair JS, Ho AL, Tse AN, et al. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell. 2009;20(8):2218-28.
109. Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol. 1997;7(3):219-21.
110. Peeper DS, Upton TM, Ladha MH, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 1997;386(6621):177-81.
111. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclindependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996;16(12):6917-25.
112. Williams JP, Stewart T, Li B, Mulloy R, Dimova D, Classon M. The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol. 2006;26(4):1170-82.
113. Takahashi C, Bronson RT, Socolovsky M, et al. Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol. 2003;23(15):5256-68.
114. Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases. Genes Cancer. 2011;2(3):232-60.
115. Wang S, Ghosh RN, Chellappan SP. Raf-1 Physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol. 1998;18(12):7487-98.
116. Dasgupta P, Sun J, Wang S, et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol. 2004;24(21):9527-41.
117. Kinkade R, Dasgupta P, Carie A, et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res. 2008;68(10):3810-8.
118. Davis R, Pillai S, Lawrence N, Sebti S, Chellappan SP. TNF-α-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle. 2012;11(1):109-18.
119. Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family proteins in stress responses and diseases. Cell Comm Signal. 2009;7(1):9.
120. Hayakawa Y, Hirata Y, Nakagawa H, et al. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc Natl Acad Sci U S A. 2011;108(2):780-5.
121. Dasgupta P, Betts V, Rastogi S, et al. Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein. J Biol Chem. 2004;279(37):38762-9.
122. Rastogi S, Rizwani W, Joshi B, Kunigal S, Chellappan SP. TNF-[alpha] response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73. Cell Death Differ. 2012;19(2):274-83.
123. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2009;21(2):140-6.
124. Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011;11(1):35-49.
125. Welch PJ, Wang JYJ. A C-terminal proteinbinding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell. 1993;75(4):779-90.
126. Welch PJ, Wang JY. Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and-independent mechanisms. Mol Cell Biol. 1995;15(10):5542-51.
127. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-abl negatively regulates cell growth. Cell. 1994;77(1):121-31.
128. Chen Y, Knudsen ES, Wang JYJ. Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB. J Biol Chem. 1996;271(33): 19637-40.
129. Knudsen ES, Wang JYJ. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996;271(14):8313-20.
130. Wang JYJ. Regulation of cell death by Abl tyrosine kinase. Oncogene. 2000;19(49):5643-50.
131. Baskaran R, Wood LD, Whitaker LL, et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature. 1997;387(6632):516-9.
132. Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997;387(6632): 520-3.
133. Nagano K, Itagaki C, Izumi T, et al. Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene. 2005;25(4):493-502.
134. Vigneri P, Wang JYJ. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-34.
135. Wang Y-T, Tsai C-F, Hong T-C, et al. An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res. 2010;9(11):5582-97.
136. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114(13):2363-73.
137. Markham D, Munro S, Soloway J, O'Connor DP, La Thangue NB. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 2006;7(2):192-8.
138. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and coregulates major cellular functions. Science. 2009;325(5942):834-40.
139. Ng S, Yue W, Oppermann U, Klose R. Dynamic protein methylation in chromatin biology. Cell Mol Life Sci. 2009;66(3):407-22.
140. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705.
141. Shi X, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007;27(4):636-46.
142. Kurash JK, Lei H, Shen Q, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell. 2008;29(3):392-400.
143. Dormann D, Madl T, Valori CF, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31(22):4258-75.
144. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet. 2000;25(3):338-42.
145. Steele-Perkins G, Fang W, Yang X-H, et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein- methyltransferase superfamily. Genes Dev. 2001;15(17):2250-62.
146. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol. 2001;21(19):6484-94.
147. Nielsen SJ, Schneider R, Bauer U-M, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature. 2001;412(6846):561-5.
148. Yoshimoto T, Boehm M, Olive M, et al. The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Exp Cell Res. 2006;312(11):2040-53.
149. Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene. 2010;29(16):2357-67.
150. Hediger F, Gasser SM. Heterochromatin protein 1: don't judge the book by its cover! Curr Opin Genet Dev. 2006;16(2):143-50.
151. Ferguson Andrew D, Larsen Nicholas A, Howard T, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011;19(9):1262-73.
152. Cho H-S, Hayami S, Toyakawa G, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation Neoplasia. 2012;14(6):476-86.
153. Komatsu S, Imoto I, Tsuda H, et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009;30(7):1139-46.
154. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6(8):731-40.
155. Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Science. 2006;97(2):113-8.
156. Boyer SN, Wazer DE, Band V. E7 Protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56(20):4620-4.
157. Kalejta RF, Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci U S A. 2003;100(6):3263-8.
158. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 1997;8(12):1277-86.
159. Knight JS, Sharma N, Robertson ES. Epstein- Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A. 2005;102(51): 18562-6.
160. Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene. 2006;25(38):5277-85.
161. Bellacchio E, Paggi MG. Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. J Cell Physiol. 2013:228(2):285-91.
162. Ying H, Xiao Z-XJ. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle. 2006;5(5):506-8.
163. Marine JC, Lozano G. Mdm2-mediated ubiquitinylation: p53 and beyond. Cell Death Differ. 2009;17(1):93-102.
164. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24(15):1580-9.
165. Tang Y-A, Lin R-K, Tsai Y-T, et al. MDM2 Overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin Cancer Res. 2012;18(16):4325-33.
166. Sdek P, Ying H, Chang DLF, et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20(5):699-708.
167. Kim W, Bennett Eric J, Huttlin Edward L, et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011;44(2):325-40.
168. Wagner SA, Beli P, Weinert BT, et al. A proteome-wide, quantitative survey of in vivo ubiquitinylation sites reveals widespread regulatory roles. Mol Cell Proteomics. 2011;10(10).
169. Praefcke GJK, Hofmann K, Dohmen RJ. SUMO playing tag with ubiquitin. Trends Biochem Sci. 2012;37(1):23-31.
170. Da Silva-Ferrada E, Lopitz-Otsoa F, Lang V, Rodrguez MS, Matthiesen R. Strategies to identify recognition signals and targets of SUMOylation. Biochem Res Int. 2012;2012:16.
171. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317-22.
172. Nagano K, Shinkawa T, Mutoh H, et al. Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics. 2009;9(10):2861-74.
173. Bennetzen MV, Larsen DH, Bunkenborg J, Bartek J, Lukas J, Andersen JS. Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics. 2010;9(6):1314-23.
174. Rigbolt KTG, Prokhorova TA, Akimov V, et al. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal. 2011;4(164):rs3.
175. Yu Y, Yoon S-O, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332(6035): 1322-6.
176. Stokes MP, Farnsworth CL, Moritz A, et al. PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. Mol Cell Proteomics. 2012;11(5):187-201.
177. Hoffert JD, Pisitkun T, Wang G, Shen R-F, Knepper MA. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci U S A. 2006;103(18):7159-64.
178. Amanchy R, Kandasamy R, Mativanan S, et al. Identification of novel phosphorylation motifs through an integrative computational and experimental analysis of the human phosphoproteome. J Proteomics Bioinform. 2011;4(2):22-35.
179. Chen R-Q, Yang Q-K, Lu B-W, et al. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res. 2009;69(6):2663-8.
180. Li H, Ren Z, Kang X, et al. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer. 2009;9(1):366.
181. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-203.
182. Amanchy R, Periaswamy B, Mathivanan S, Reddy R, Tattikota SG, Pandey A. A curated compendium of phosphorylation motifs. Nat Biotech. 2007;25(3):285-6.
183. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074-80.
184. Sims RJ, Reinberg D. Is there a code embedded in proteins that is based on posttranslational modifications? Nat Rev Mol Cell Biol. 2008;9(10):815-20.
185. Jin J, Pawson T. Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci. 2012;367(1602):2540-55.
186. Yaffe MB, Elia AEH. Phosphoserine/threonine-binding domains. Curr Opin Cell Biol. 2001;13(2):131-8.
187. Gardino AK, Yaffe MB. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biology. 2011;22(7):688-95.
188. Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol. 2002;3(3):177-8s6.